Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Prostate cancer is a common type of cancer in males ... Cancer staging is complex and accounts for many different factors. Usually, the lower the number, the less the cancer has spread.

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was ...

Brain metastases from prostate cancer (PC) seem to be more frequent ... The difference should be critically viewed because of the different patient selection criteria. The increasing trend of ...

But a new genetic test appears capable of sussing out which men are at greater risk of urinary side effects from radiation ...

“This type of precision medicine is a game changer for people whose prostate cancer has spread outside of the prostate ... and instead switch to a different hormonal therapy. This trial suggests ...

The researchers also found that different genetic factors are linked to different types of side effects ... to confirm that PROSTOX works in a new group of 148 patients with prostate cancer receiving ...

Local anesthetic transperineal (LATP) biopsy for prostate ... cancer," the study authors wrote. "The TRANSLATE trial provides randomized controlled trial [RCT] evidence regarding which type ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Medically reviewed by Matthew Wosnitzer, MD Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of ...